Evidence map›Paper›PMID 40702202›Full record

ArticleAnnals of surgical oncology2025

Adverse In-hospital Outcomes According to Pelvic Lymph Node Dissection at Partial Cystectomy.

Andrea Marmiroli, Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Michele Nicolazzini, Calogero Catanzaro, Federico Polverino, Jordan A Goyal, Stefano Luzzago, Francesco Alessandro Mistretta and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Andrea MarmiroliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. andrea.marmiroli@unimi.it.
Mattia LongoniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Quynh Chi LeCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Fabian FalkenbachCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Federico PolverinoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Stefano LuzzagoDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Francesco Alessandro MistrettaDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Mattia PiccinelliDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Alberto BrigantiVita-Salute San Raffaele University, Milan, Italy.
Felix K H ChunDepartment of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Carlotta PalumboDivision of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
Riccardo SchiavinaDivision of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy.
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Gennaro MusiDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study was designed to test the association between adverse in-hospital outcomes and pelvic lymph node dissection (PLND) at partial cystectomy (PC) for nonmetastatic bladder cancer (BCa).

methodsWe identified patients treated with PC for BCa (National Inpatient Sample 2012-2019). First, estimated annual percentage changes (EAPC) tested temporal trends of PLND at PC. Second, descriptive analyses, propensity score matching (PSM, ratio 1:2) and multivariable logistic regression models (LRMs) were used.

resultsOf 1,289 BCa patients treated with PC, 201 (16.0%) underwent PLND. The rates of PLND at PC decreased from 24.8 to 5.4% over the study span (EAPC - 11.3%; p = 0.01). Pelvic lymph node dissection patients were younger (67 vs. 71 years old; p < 0.001), exhibited a lower number of comorbidities (Charlson Comorbidity Index [CCI] 0: 41% vs. 38%; p = 0.006), and were more frequently admitted to teaching (83% vs. 76%; p = 0.03) and large bedsize (69% vs. 57%; p = 0.004) hospitals. After PSM, 201 of 201 (100%) PLND vs. 402 of 1,088 (36.9%) no-PLND at PC patients were included in further analyses. Pelvic lymph node dissection at PC patients only exhibited significantly higher rate of intraoperative complications (9% vs. 3.7%; p = 0.008), but no statistically significant differences in 13 of 14 other categories were recorded (all p values > 0.09). In multivariable LRMs, PLND independently predicted 2.6-fold higher rate of intraoperative complications (p = 0.01).

conclusionsThe rate of PLND drastically decreased over time. PLND vs. no-PLND at PC only resulted in a moderate increase in intraoperative complications without differences in 13 other adverse in-hospital outcomes, which included complications, in-hospital mortality, length of stay, and total hospital charges.

Indexed as

CystectomyHospital MortalityLymph Node ExcisionLymph NodesPostoperative ComplicationsUrinary Bladder NeoplasmsAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPelvisPrognosisRetrospective StudiesSurvival RateBladder cancerNISPartial cystectomyPLND

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.